Search Results - "Ringe, J"

Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) by Rizzoli, R., Boonen, S., Brandi, M.-L., Bruyère, O., Cooper, C., Kanis, J.A., Kaufman, J.-M., Ringe, J.D., Weryha, G., Reginster, J.-Y.

“…Abstract Background:Vitamin D insufficiency has deleterious consequences on health outcomes. In elderly or postmenopausal women, it may exacerbate…”
Get full text

Efficacy and Safety of Strontium Ranelate in the Treatment of Osteoporosis in Men by Kaufman, J.-M, Audran, M, Bianchi, G, Braga, V, Diaz-Curiel, M, Francis, R. M, Goemaere, S, Josse, R, Palacios, S, Ringe, J. D, Felsenberg, D, Boonen, S

“…Context: Strontium ranelate reduces vertebral and nonvertebral fracture risk in postmenopausal osteoporosis. Objective: The objective of this study was to…”
Get full text

The position of strontium ranelate in today’s management of osteoporosis by Reginster, J.-Y., Brandi, M.-L., Cannata-Andía, J., Cooper, C., Cortet, B., Feron, J.-M., Genant, H., Palacios, S., Ringe, J. D., Rizzoli, R.

“…Osteoporosis accounts for about 3 % of total European health-care spending. The low proportion of costs for the pharmacological prevention of osteoporotic…”
Get full text

Genome-wide expression profiling reveals new candidate genes associated with osteoarthritis by Karlsson, C, Dehne, T, Lindahl, A, Brittberg, M, Pruss, A, Sittinger, M, Ringe, J

“…Summary Introduction Although the extracellular matrix (ECM) is the functional element in articular cartilage and its degradation is central in the…”
Get full text

A reappraisal of generic bisphosphonates in osteoporosis by Kanis, J. A., Reginster, J.-Y., Kaufman, J.-M., Ringe, J.-D., Adachi, J. D., Hiligsmann, M., Rizzoli, R., Cooper, C.

“…Summary The competitive price of generic bisphosphonates has had a marked effect on practice guidelines, but an increasing body of evidence suggests that they…”
Get full text

Treatment of osteoporosis in men by Kaufman, J.-M, Reginster, J.-Y, Boonen, S, Brandi, M.L, Cooper, C, Dere, W, Devogelaer, J.-P, Diez-Perez, A, Kanis, J.A, McCloskey, E, Mitlak, B, Orwoll, E, Ringe, J.D, Weryha, G, Rizzoli, R

“…Abstract Summary Aspects of osteoporosis in men, such as screening and identification strategies, definitions of diagnosis and intervention thresholds, and…”
Get full text

Chemokine profile of synovial fluid from normal, osteoarthritis and rheumatoid arthritis patients: CCL25, CXCL10 and XCL1 recruit human subchondral mesenchymal progenitor cells by Endres, M, Andreas, K, Kalwitz, G, Freymann, U, Neumann, K, Ringe, J, Sittinger, M, Häupl, T, Kaps, C

“…Summary Objective The microfracture technique activates mesenchymal progenitors that enter the cartilage defect and form cartilage repair tissue. Synovial…”
Get full text

Gypsum-DL: an open-source program for preparing small-molecule libraries for structure-based virtual screening by Ropp, Patrick J., Spiegel, Jacob O., Walker, Jennifer L., Green, Harrison, Morales, Guillermo A., Milliken, Katherine A., Ringe, John J., Durrant, Jacob D.

“…Computational techniques such as structure-based virtual screening require carefully prepared 3D models of potential small-molecule ligands. Though powerful,…”
Get full text

Therapies with CCL25 require controlled release via microparticles to avoid strong inflammatory reactions by Spinnen, J, Fröhlich, K, Sinner, N, Stolk, M, Ringe, J, Shopperly, L, Sittinger, M, Dehne, T, Seifert, M

“…Chemokine therapy with C-C motif chemokine ligand 25 (CCL25) is currently under investigation as a promising approach to treat articular cartilage…”
Get full text

Efficacy of risedronate in men with primary and secondary osteoporosis : results of a 1-year study by RINGE, J. D, FABER, H, FARAHMAND, P, DORST, A

“…Osteoporosis is prevalent in men with an estimated one in eight men older than 50 years suffering from osteoporotic fracture, and a higher mortality rate after…”
Get full text

Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile by Ringe, J. D., Farahmand, P.

“…Almost 50 % of osteoporosis (OP) patients discontinue bisphosphonate (BP) therapy within 1–2 years after the start of their treatment. Denosumab’s longer…”
Get full text

Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate by RINGE, J. D, DORST, A, FABER, H

“…Localized transient osteoporosis (LTO; bone marrow edema syndrome) is a rare disorder of generally unknown etiology that is characterized by acute onset of…”
Get full text

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study by RINGE, J. D, DORST, A, FABER, H, IBACH, K, SORENSON, F

“…Despite its well-known benefits, chronic corticosteroid therapy causes osteoporotic fractures in approximately 30-50% of patients treated. To prevent the…”
Get full text

Management of osteoporosis of the oldest old by Rizzoli, R., Branco, J., Brandi, M.-L., Boonen, S., Bruyère, O., Cacoub, P., Cooper, C., Diez-Perez, A., Duder, J., Fielding, R. A., Harvey, N. C., Hiligsmann, M., Kanis, J. A., Petermans, J., Ringe, J. D., Tsouderos, Y., Weinman, J., Reginster, J.-Y.

“…Summary This consensus article reviews the diagnosis and treatment of osteoporosis in geriatric populations. Specifically, it reviews the risk assessment and…”
Get full text

Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis by Farahmand, P., Marin, F., Hawkins, F., Möricke, R., Ringe, J. D., Glüer, C.-C., Papaioannou, N., Minisola, S., Martínez, G., Nolla, J. M., Niedhart, C., Guañabens, N., Nuti, R., Martín-Mola, E., Thomasius, F., Peña, J., Graeff, C., Kapetanos, G., Petto, H., Gentzel, A., Reisinger, A., Zysset, P. K.

“…Summary Changes of the bone formation marker PINP correlated positively with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis…”
Get full text

Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis by VAN LINTHOUT, S, SAVVATIS, K, MITEVA, K, PENG, J, RINGE, J, WARSTAT, K, SCHMIDT-LUCKE, C, SITTINGER, M, SCHULTHEISS, H.-P, TSCHÖPE, C

“…Coxsackievirus B3 (CVB3)-induced myocarditis, initially considered a sole immune-mediated disease, also results from a direct CVB3-mediated injury of the…”
Get full text

Strontium ranelate: an effective solution for diverse fracture risks by Ringe, J. D.

“…Osteoporosis is listed by the WHO among the ten most frequent and socio-economically important, chronic diseases of mankind. The term osteoporosis however…”
Get full text

Alendronate Treatment of Established Primary Osteoporosis in Men: Results of a 2-Year Prospective Study by Ringe, J. D., Faber, H., Dorst, A.

“…Men with osteoporosis have been neglected in the past, and only a few therapeutic trials have been performed in men. The bisphosphonate, alendronate, has been…”
Get full text

Microencapsulation and chondrogenic differentiation of human mesenchymal progenitor cells from subchondral bone marrow in Ca-alginate for cell injection by Endres, M., Wenda, N., Woehlecke, H., Neumann, K., Ringe, J., Erggelet, C., Lerche, D., Kaps, C.

“…The application of stem cells is a promising therapeutic approach for cartilage regeneration. For cell therapies, a biocompatible injectable carrier, which…”
Get full text

Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis by Kastrinaki, M-C, Sidiropoulos, P, Roche, S, Ringe, J, Lehmann, S, Kritikos, H, Vlahava, V-M, Delorme, B, Eliopoulos, G D, Jorgensen, C, Charbord, P, Häupl, T, Boumpas, D T, Papadaki, H A

“…Bone marrow (BM) mesenchymal stem cells (MSCs) are being considered as potential therapeutic agents in various inflammatory autoimmune diseases for their…”
Get more information